Medinatura New Mexico, Inc.

Warning LetterOpen

Mr. Clifford Clive CEO Medinatura New Mexico, Inc. 10421 Research Road SE Albuquerque , NM 87123 United StatesFEI 1626962Issued Dec 10, 2025Center for Drug Evaluation and Research (CDER)

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 1626962.

Violations4

Issue DateDec 10, 2025

Product TypeDrugs

StatusOpen

Letter Details

Firm: Medinatura New Mexico, Inc.
Location: Mr. Clifford Clive CEO Medinatura New Mexico, Inc. 10421 Research Road SE Albuquerque , NM 87123 United States
FEI Number: 1626962
Country: United States
Issue Date: December 10, 2025
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Summary

Medinatura New Mexico, Inc. received a warning letter for current Good Manufacturing Practice (CGMP) violations in the production of finished pharmaceutical drugs, specifically homeopathic products. During a May 2025 inspection, the FDA identified critical failures in component testing, including inadequate identity testing of incoming materials and active pharmaceutical ingredients, as well as failure to validate the reliability of suppliers' test analyses at appropriate intervals as required by 21 CFR 211.84. The firm's testing procedures were limited and relied heavily on supplier certificates of analysis without establishing their reliability, resulting in the determination that the drug products were adulterated under the Federal Food, Drug, and Cosmetic Act.

Medinatura New Mexico, Inc. FDA Warning Letter, December 10, 2025